ÆÄŲ½¼º´ ¼ö¼ú¹ý ¹è¿ì·Á °¢±¹ ÀÇ»çµéÀÌ Ã£´Â
ÁÖ¿ä Áø·á ºÐ¾ß´Â ³úÁ¾¾ç, ³úÇϼöüÁ¾¾ç, ÆÄŲ½¼º´ÀÌ´Ù. 2004³â ³ú½ÉºÎÀڱؼúÀÌ º¸Çè¿¡ µîÀçµÅ ÆÄŲ½¼ ȯÀÚ¸¦ Æ÷ÇÔÇÑ ÀÌ»ó¿îµ¿Áúȯ ȯÀÚµéÀÌ º»°ÝÀûÀ¸·Î ³ú½ÉºÎÀڱؼúÀ» ½ÃÇà¹Þ±â ½ÃÀÛÇÒ ¹«·Æ 24½Ã°£ ¸ð´ÏÅ͸µ unitÀ» °®Ãá ¼¼°èÀû ¼öÁØÀÇ ÆÄŲ½¼ ¼¾Å͸¦ °³¼ÒÇØ ȯÀÚµéÀÇ ÀüÀÎÀû °ü¸®¸¦ ½ÃÇàÇϰí ÀÖ´Ù.
¾Æ½Ã¾Æ ÃÖÃÊ·Î ¾Æ½Ã¾Æ °¢±¹¿¡¼ ¸ðÀÎ ÀÇ»çµé¿¡°Ô ³ú½ÉºÎÀڱؼú ¶óÀÌºê ¼ö¼ú ±³À°À» Çϱ⵵ Çß´Ù. ³ú½ÉºÎÀڱؼúÀº ³ú¿¡ Àü±ØÀ» ³ÖÀº ÈÄ Àü±ØÀÚ±ØÀ» Áà ºñÁ¤»óÀûÀ¸·Î Ȱ¼ºÈµÈ ÆÄŲ½¼º´ ȯÀÚÀÇ ½Å°æ¼¼Æ÷¸¦ ¾ïÁ¦ÇÏ´Â ¼ö¼úÀÌ´Ù.
Á¦ ¸ñ | Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2020.04.01 | ¹ßÇ¥Áö | Nat Genet |
Á¦ ¸ñ | STAT3 Inhibitor ODZ10117 Suppresses Glioblastoma Malignancy and Prolongs Survival in a Glioblastoma Xenograft Model | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2020.03.15 | ¹ßÇ¥Áö | Cells |
Á¦ ¸ñ | Determination of Parkinson Disease Laterality After Deep Brain Stimulation Using 123I FP-CIT SPECT | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2020.02.27 | ¹ßÇ¥Áö | Clin Nucl Med |
Á¦ ¸ñ | Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2020.02.04 | ¹ßÇ¥Áö | J Neurooncol. |
Á¦ ¸ñ | Aberrant Tonic Inhibition of Dopaminergic Neuronal Activity Causes Motor Symptoms in Animal Models of Parkinson's Disease | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2020.01.07 | ¹ßÇ¥Áö | Curr Biol |
Á¦ ¸ñ | Secreted protein acidic and rich in cysteine mediates active targeting of human serum albumin in U87MG xenograft mouse models | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2019.10.11 | ¹ßÇ¥Áö | Theranostics |
Á¦ ¸ñ | Sex differences in the short-term and long-term effects of subthalamic nucleus stimulation in Parkinson's disease | ||
---|---|---|---|
¹ßÇ¥³âµµ | 2019.09.30 | ¹ßÇ¥Áö | Parkinsonism Relat Disord |
¼¿ï´ëº´¿øÀº º»¿øÀ» ºñ·ÔÇÑ ¾î¸°À̺´¿ø, ¾Ïº´¿ø, ÀÇ»ý¸í¿¬±¸¿øÀ¸·Î ±¸¼ºµÅ ÀÖ´Â Á¾ÇÕ ÀÇ·á±â°üÀ¸·Î 1786º´»ó ±Ô¸ð¸¦ °®Ãß°í ÀÖ´Ù. 540¿© ¸íÀÇ ±³¼ö¿Í 5400¿© ¸íÀÇ Á÷¿øÀÌ ÇÏ·ç Æò±Õ 1700¿© ¸íÀÇ ÀÔ¿øÈ¯ÀÚ¿Í 8600¸íÀÌ ³Ñ´Â ¿Ü·¡È¯ÀÚ¸¦ µ¹º¸°í ÀÖ´Ù. ¼¼°èÀû ÷´Ü Áø·á ¿µ¿ªÀ» Áö¼ÓÀûÀ¸·Î È®º¸ÇÔÀ¸·Î½á ÃÖ»óÀÇ Áø·á ¼ºñ½º¸¦ Á¦°øÇϰí, ¿ì¸®³ª¶ó ÀÇ·á ¼±ÁøÈ¸¦ Ãß±¸ÇÏ´Â Á¤Ã¥ Çù·Â º´¿øÀÌ´Ù.
¼¿ïƯº°½Ã Á¾·Î±¸ ´ëÇзΠ101